Clinical trial
Saftey and Efficacy Phase II Study of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
NCT01918241 is registered in ClinicalTrials.gov with Hangzhou Jiuyuan Gene Engineering Co. Ltd., as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Saftey and Efficacy Phase II Study of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
- Lead sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 31, 2013
- Completion date
- Not reported
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.